Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is 2,71ย โฌ. In 2022 the company made an earnings per share (EPS) of 2,06ย โฌ an increase over its 2021 EPS that were of 1,89ย โฌ.